Euro Ewing Consortium

International Clinical Trials to Improve Survival from Ewing Sarcoma

Young researchers funded by Peter Pan charity at July 2016 EEC meeting

The EURO EWING Consortium aims to encourage collaboration across Europe and is grateful to the Peter Pan charity in Italy for providing financial support to allow young researchers from across Europe, working on Ewing sarcoma, to present their work at EEC meetings.

The first round of successful applicants presented at the EEC meeting in Brussels in July 2016.

Florence Cidre Aranaz

Carlos III Health Institute, Spain
EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma

" Attending the ECC Meeting in Brussels has been an overall great experience, and for that I would like to thank the Peter Pan charity for their support. During the Meeting I had the chance to attend presentations given by highly specialised researchers, as well as detailed updates on the different programmes that have been taking place at the EEC, which has helped me broaden my understanding on how the EEC as a whole is working towards its goal. Since I was also selected to present my work as a junior researcher, I was able to potentiate its visibility and to discuss it with other scientists in the field. Finally, attending the EEC Meeting has helped me strengthen the existing relationships with other Ewing sarcoma groups, which opens the possibility to engage into new fruitful collaborations.
F Cidre Aranaz

Dr Alessandro Parra

Istituto Ortopedico Rizzoli, Italy
Analysis of CD99 SNPs as a mean for predicting the Ewing Sarcoma risk

" The participation to the Euro Ewing Consortium meeting, held in Brussels at the EORTC centre has been very helpful to me in order to enlarge my knowledge about the Ewing Sarcoma biology and about the strategies that are currently under study for the cure of this type of sarcoma. The meeting was divided principally into two main sections: the organising part with the technical description of the milestones and the progress of the different work packages of the project and the scientific session in which I have presented my contribution in the genetic field of the Ewing sarcoma biology study. The meeting has been very important to me in order to get in touch for the first time with the other partners due to my relatively late access to the project. The organising-technical part of the meeting has been very clear helping me to understand the project state-of-the-art, the needs for improving the results and the reaching of the milestones and deliverables of the project even if I have entered the project from little time. Moreover we had the important opportunity to have the pleasure to meet three representatives of the patient association making me even more conscious that the research in the Ewing sarcoma field is principally devoted to improve knowledge and therefore the therapies for granting to patients some more powerful solutions to fight against the disease.
A Parra

Dr Stefan Zoellner

University Hospital Munster, Germany

Small molecule inhibition of EWS-FLI1 leads to G2/M cell cycle arrest and enhanced vincristine sensitivity in Ewing sarcoma

" First, I would like to thank the Peter Pan Onlus charity in Italy for the financial support to attend and present as young researcher at the EURO EWING Consortium meeting 2016 in Brussels. Attendance has been both professionally and personally very worthwhile. As a clinician it was interesting to witness the trans-national coordination of the therapeutic directive for Ewing sarcoma in Europe as well as the decision-making process for new substances to include in the protocol in order to ameliorate the fate for Ewing sarcoma patients. Both obstacles, e.g. regarding the different national standards to collect bio specimen, and chances, e.g. improving the scientific output by intellectual exchange and collaboration, are part of the challenging execution of the EURO EWING study and warrant further amelioration or exploration, respectively. Also, I valued the participation and interaction with patient advocates. The concerns and questions of patients and caregivers are important as their input is unbiased from scientific interests and should be considered in the study process; their presence also represents a constant reminder that there is still an urgent need for new therapeutics. Finally, having the opportunity to present my own scientific project and receive a constructive feedback from experienced colleagues was very fulfilling and helpful. For example, a pathologist gave valuable input on the observed cell morphology of my tissue slides. Based on this exchange of information and acquisition of expertise from established researchers I was able to build networks that may lead to new scientific collaborations.
S Zoellner 2016

Photos courtesy of Ian Randall Photography.

The call for applications for travel funding to attend the next EEC meeting (18 & 19 January 2017 in central London) will open in November 2016 and will be advertised on the EEC website.